Author:
Abdullaev Amir G.,Shakhpazyan N. K,Polockiy B. E,Mekheda L. V,Davydov M. I
Abstract
The article analyzes the molecular genetic features ofperitoneal mesothelioma in order to identify differential diagnostic signs of the disease, to identify the factors of tumor growth, as well as identifying ways to improve current treatments.
Reference55 articles.
1. http://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=pleura&ss=all&hn=mesothelioma&sh=all&in=t&src=tissue
2. http://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=peritoneum&ss=all&hn=mesothelioma&sh=all&in=t&src=tissue
3. Janne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J. Polikoff J.A. et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin. Lung. Cancer. 2005; 7(1): 40-6.
4. Foster J.M., Radhakrishna U., Govindarajan V., Carreau J.H., Gatalica Z., Sharma P. et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J. Surg. Oncol. 2010; 8: 88.
5. Enomoto Y., Kasai T., Takeda M., Takano M., Morita K., Kadota E. et al. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol. Int. 2012; 62(4): 226-31.